The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 101–200 of 1,002
Precision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 244
Self-citationIyer, P. C., Dadu, R., Gule-Monroe, M. K., Busaidy, N. L., Ferrarotto, R., Habra, M. A., Zafereo, M., Williams, M. D., Gunn, G. B., Grosu, H. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0378-y · Cited by 239
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
Self-citationRodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
An overview of precision oncology basket and umbrella trials for clinicians
Park, J., Hsu, G. G., Siden, E. G., Thorlund, K., & Mills, E. J. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21600 · Cited by 239
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Durham, B. H., Lopez-Rodrigo, E., Picarsic, J. L., Abramson, D. H., Rotemberg, V. M., Munck, S. D., Pannecoucke, E., Lu, S. X., Pastore, A., Yoshimi, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0653-6 · Cited by 231
Self-citationClinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., Patton, D. R., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz245 · Cited by 227
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
Self-citationHong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Self-citation3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets
Gao, J., Chang, M. T., Johnsen, H. C., Gao, S. P., Sylvester, B. E., Sümer, S. O., Zhang, H., Solit, D. B., Taylor, B. S., Schultz, N. D., et al. (2017) · Genome Medicine · doi:10.1186/s13073-016-0393-x · Cited by 220
Grothey, A. F., Fakih, M., & Tabernero, J. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.206 · Cited by 220
Self-citationDudnik, E., Peled, N., Nechushtan, H., Wollner, M., Onn, A., Agbarya, A., Moskovitz, M. T., Keren, S., Popovits‐Hadari, N., Urban, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.024 · Cited by 221
Aubart, F. C., Emile, J., Carrat, F., Charlotte, F., Benameur, N., Donadieu, J., Maksud, P., Idbaïh, A., Barète, S., Hoang‐Xuan, K., et al. (2017) · Blood · doi:10.1182/blood-2017-03-771873 · Cited by 211
Boscoe, A. N., Rolland, C., & Kelley, R. K. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.10 · Cited by 210
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Lenvatinib: Role in thyroid cancer and other solid tumors
Cabanillas, M. E., & Habra, M. A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.003 · Cited by 216
Histiocytoses: emerging neoplasia behind inflammation
Haroche, J., Aubart, F. C., Rollins, B. J., Donadieu, J., Charlotte, F., Idbaïh, A., Vaglio, A., Abdel-Wahab, O. I., Emile, J., & Amoura, Z. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30031-1 · Cited by 208
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V. L., Ferraro, R., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30496-0 · Cited by 221
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
Wu, J., & Lin, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315056 · Cited by 217
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J. M., Burke, K. P., Jorgji, V., Sindurakar, P., Braverman, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02181-8 · Cited by 205
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 199
Remón, J., Rhun, É. L., & Besse, B. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.006 · Cited by 196
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E. S., Alva, A. S., Janeway, K. A., Stella, P. J., Voest, E. E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 199
Trédan, O., Wang, Q., Pissaloux, D., Cassier, P. A., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz080 · Cited by 194
Self-citationThe next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment
Rodriguez, H., Zenklusen, J. C., Staudt, L. M., Doroshow, J. H., & Lowy, D. R. (2021) · Cell · doi:10.1016/j.cell.2021.02.055 · Cited by 197
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
Mazières, J., Cropet, C., Montané, L., Barlési, F., Souquet, P. J., Quantin, X., Dubos‐Arvis, C., Otto, J., Favier, L., Avrillon, V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.022 · Cited by 190
Self-citationCurrent Landscape of Targeted Therapy in Lung Cancer
Mayekar, M. K., & Bivona, T. G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.810 · Cited by 184
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Schwaederle, M. C., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0795 · Cited by 184
Biomarkers for Hepatobiliary Cancers
Nault, J., & Villanueva, A. (2020) · Hepatology · doi:10.1002/hep.31175 · Cited by 181
Precision oncology based on omics data: The NCT Heidelberg experience
Horak, P., Klink, B., Heining, C., Gröschel, S., Hutter, B., Fröhlich, M., Uhrig, S., Hübschmann, D., Schlesner, M., Eils, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30828 · Cited by 179
Schrock, A. B., Li, S. D., Frampton, G. M., Suh, J. H., Braun, E., Mehra, R., Buck, S. C., Bufill, J. A., Peled, N., Karim, N. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.005 · Cited by 176
The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Kim, A., & Cohen, M. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1201057 · Cited by 178
Real-World Evidence in Oncology: Opportunities and Limitations
Maïo, M. D., Perrone, F., & Conte, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0647 · Cited by 181
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Waguespack, S. G., Drilon, A., Lin, J. J., Brose, M. S., McDermott, R., Almubarak, M., Bauman, J., Casanova, M., Krishnamurthy, A., Kummar, S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1259 · Cited by 188
The evidence framework for precision cancer medicine
Moscow, J. A., Fojo, T., & Schilsky, R. L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.186 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Boussios, S., Öztürk, M. A., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K. H., Christodoulou, D. K., & Pavlidis, N. A. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010012 · Cited by 172
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
Yates, L. R., Seoane, J., Tourneau, C. L., Siu, L. L., Marais, R., Michiels, S., Soria, J., Campbell, P. J., Normanno, N., Scarpa, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx707 · Cited by 167
Current and emerging therapies for advanced biliary tract cancers
Kam, A. E., Masood, A., & Shroff, R. T. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00171-0 · Cited by 170
Janiaud, P., Serghiou, S., & Ioannidis, J. P. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.003 · Cited by 168
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
“A recent vemurafenib BRAFV600E basket trial showed that 42% of lung cancers with the BRAF V600E mutation responded to vemurafenib (Hyman et al., 2015).”
BackgroundBRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
Caputo, F., Santini, C., Bardasi, C., Cerma, K., Gardini, A. C., Spallanzani, A., Andrikou, K., Cascinu, S., & Gelsomino, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215369 · Cited by 169
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Molecular biomarkers for lung adenocarcinoma
Calvayrac, O., Pradines, A., Tostivint, E. P., Mazières, J., & Guibert, N. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 160
McClain, K. L., Bigenwald, C., Collin, M. P., Haroche, J., Marsh, R. A., Mérad, M., Picarsic, J. L., Ribeiro, K. B., & Allen, C. E. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00307-9 · Cited by 163
Brady, D. C., Crowe, M. S., Greenberg, D. N., & Counter, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1190 · Cited by 159
Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0032 · Cited by 156
Self-citationUpdates on the Management of Thyroid Cancer
Araque, K., Gubbi, S., & Kłubo-Gwieździńska, J. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1089-7870 · Cited by 162
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
Horak, P., Fröhling, S., & Glimm, H. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000094 · Cited by 162
Current understanding and management of pulmonary Langerhans cell histiocytosis
Vassallo, R., Harari, S. A., & Tazi, A. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210125 · Cited by 158
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma
Rao, S. N., Zafereo, M., Dadu, R., Busaidy, N. L., Hess, K. R., Cote, G. J., Williams, M. D., William, W. N., Sandulache, V. C., Gross, N. D., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0395 · Cited by 154
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
Papo, M., Diamond, E. L., Aubart, F. C., Emile, J., Roos‐Weil, D., Gupta, N., Durham, B. H., Özkaya, N., Doǧan, A., Ulaner, G. A., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761718 · Cited by 157
Self-citationPersonalized therapy for lung cancer: striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 154
Going Digital: A Survey on Digitalization and Large-Scale Data Analytics in Healthcare
Volker Tresp, C., Overhage, J. M., Bundschus, M., Rabizadeh, S., Fasching, P. A., & Yu, S. (2016) · Proceedings of the IEEE · doi:10.1109/jproc.2016.2615052 · Cited by 162
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics
van den Bent, M. J., Weller, M., Wen, P. Y., Kros, J. M., Aldape, K. D., & Chang, S. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now277 · Cited by 156
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Prasad, V. K., Kaestner, V., & Mailankody, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4182 · Cited by 144
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Molecular Diagnostics in Clinical Oncology
Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 151
Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment
Nakaguro, M., Tada, Y., Faquin, W. C., Sadow, P. M., Wirth, L. J., & Nagao, T. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22288 · Cited by 143
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 150
The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
Meyer, E. L., Mesenbrink, P. G., Dunger‐Baldauf, C., Fülle, H., Glimm, E., Li, Y., Posch, M., & König, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.010 · Cited by 141
Emile, J., Aubart, F. C., Collin, M. P., Fraitag, S., Idbaïh, A., Abdel-Wahab, O. I., Rollins, B. J., Donadieu, J., & Haroche, J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00311-1 · Cited by 138
Irmisch, A., Bonilla, X., Chevrier, S., Lehmann, K.-V., Singer, F., Toussaint, N. C., Esposito, C., Mena, J., Milani, E. S., Casanova, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.004 · Cited by 138
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
Tissot, C., Couraud, S., Tanguy, R., Bringuier, P., Girard, N., & Souquet, P.-J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.006 · Cited by 138
Durham, B. H., Roos‐Weil, D., Baillou, C., Aubart, F. C., Yoshimi, A., Miyara, M., Papo, M., Hélias‐Rodzewicz, Z., Terrones, N., Özkaya, N., et al. (2017) · Blood · doi:10.1182/blood-2016-12-757377 · Cited by 134
Self-citationUtility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
Kato, S., Krishnamurthy, N., Banks, K. C., De, P. K., Williams, K. A., Williams, C. B., Leyland-Jones, B. R., Lippman, S. M., Lanman, R. B., & Kurzrock, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0628 · Cited by 134
Langerhans cell histiocytosis in children
Krooks, J., Minkov, M., & Weatherall, A. G. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.060 · Cited by 133
Kurzrock, R., Bowles, D. W., Kang, H., Meric‐Bernstam, F., Hainsworth, J. D., Spigel, D. R., Bose, R., Burris, H. A., Sweeney, C. J., Beattie, M. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.018 · Cited by 133
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 133
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
Cunanan, K. M., Gönen, M., Shen, R., Hyman, D. M., Riely, G. J., Begg, C. B., & Iasonos, A. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9751 · Cited by 130
Self-citationVariant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 131
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicińska, E., Sulahian, R., Goodale, A. B., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 129
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 129
Self-citationGenomic alterations in thyroid cancer: biological and clinical insights
Landa, I., & Cabanillas, M. E. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00920-6 · Cited by 134
Schmidt, K. T., Chau, C. H., Price, D. K., & Figg, W. D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.765 · Cited by 129
Targeted Therapy and Immunotherapy for Lung Cancer
Naylor, E. C., Desani, J., & Chung, P. K. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.011 · Cited by 129
Molecular Pathology of Primary Non-small Cell Lung Cancer
Suster, D. I., & Mino-Kenudson, M. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.004 · Cited by 130
Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient
Peck, R. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052446 · Cited by 125
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma
Iyer, P. C., Dadu, R., Ferrarotto, R., Busaidy, N. L., Habra, M. A., Zafereo, M., Gross, N. D., Hess, K. R., Gule-Monroe, M. K., Williams, M. D., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0285 · Cited by 125
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz, S., Yoshino, T., Cutsem, E. V., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R. D., Maughan, T., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03443-3 · Cited by 133
Self-citationEncorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Roviello, G., D’Angelo, A., Petrioli, R., Roviello, F., Cianchi, F., Nobili, S., Mini, E., & Lavacchi, D. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100795 · Cited by 129
Wang, K., Russell, J. S., McDermott, J. D., Elvin, J. A., Khaira, D., Johnson, A., Jennings, T. A., Ali, S. M., Murray, M., Marshall, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2568 · Cited by 123
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Olaussen, K. A., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw321 · Cited by 124
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Molecular pathology of lung cancer: current status and perspectives
Oberndorfer, F., & Müllauer, L. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000429 · Cited by 122
Precision medicine becomes reality—tumor type‐agnostic therapy
Li, Y., & Zhang, W. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0274-3 · Cited by 121
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 123
Moon, I., LoPiccolo, J., Baca, S. C., Sholl, L. M., Kehl, K. L., Hassett, M. J., Liu, D., Schrag, D., & Gusev, A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02482-6 · Cited by 122
Management of borderline ovarian tumours
Gershenson, D. M. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.09.012 · Cited by 119
Tong, L., Ding, N., Tong, X., Li, J., Zhang, Y., Wang, X., Xu, X., Ye, M., Li, C., Wu, X., et al. (2019) · Theranostics · doi:10.7150/thno.34070 · Cited by 120
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
